Treatment Personalization Is Poised to Define New Era of mCRC Therapy
New combination regimens for patients with metastatic colorectal cancer (mCRC) who have experienced disease progression after frontline therapy are emerging that include tyrosine kinase inhibitors (TKIs), EGFR and VEGF inhibitors, and novel agents as …